ProCE Banner Activity

Advancing Care in Prostate Cancer: Aligning Your Practice With Rapidly Evolving Standards of Care Throughout the Disease Continuum

In this on-demand Webcast of a CCO symposium at ASCO 2018, Michael J. Morris, MD; Charles J. Ryan, MD; and Oliver Sartor, MD, review and discuss the latest data on managing men with prostate cancer, including high-risk nonmetastatic disease, metastatic disease, and emerging biomarkers.

Released: July 13, 2018

Expiration: July 12, 2019

No longer available for credit.

Share

Faculty

Oliver Sartor

Oliver Sartor, MD

C.E. and Bernadine Laborde Professor of Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Michael J. Morris

Michael J. Morris, MD

Associate Professor
Prostate Cancer Section Head
Clinical Director

GU Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by educational grants from

Astellas Text

sanofiaventis

Learning Objectives

  • Effectively determine individualized treatment plans for patients with prostate cancer using the latest agents in appropriate sequences or combinations in accordance with up-to-date evidence and expert recommendations throughout the disease continuum
  • Evaluate recent practice-changing clinical trial findings concerning novel compounds or strategies to manage castration-resistant prostate cancer, including hormone, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Refer appropriate patients with prostate cancer to ongoing clinical trials of assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Program Director Disclosure

Program Director

Oliver Sartor, MD

C.E. and Bernadine Laborde Professor of Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Oliver Sartor, MD, has disclosed that he has received grants/research support from and has been a principal investigator for Bayer, Endocyte, Johnson & Johnson, Sanofi, and Sotio and has received consulting fees from Astellas, Bavarian Nordic, Bayer, Bellicum, Johnson & Johnson, and Medivation.

Faculty Disclosure

Primary Author

Michael J. Morris, MD

Associate Professor
Prostate Cancer Section Head
Clinical Director

GU Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Morris, MD, has disclosed that he has received funds for research from Bayer, Corcept, Endocyte, Genentech/Roche, and Progenics; and that he is a member of the advisory board at Advanced Accelerator Applications, Bayer, Endocyte, and Progenics.

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has been a principal investigator for Clovis, has received honoraria from Janssen, and has served on the editorial board of UroToday.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.